JPRN-jRCT2051200105招募中1 期
Phase I / IIa, single-institution, open-label study to explore the safety and efficacy of R-OKY-034F long-term administration in patients with refractory / intolerable and surgically unresectable pancreatic cancer with standard chemotherapy
Kusaka Haruki0 个研究点目标入组 30 人开始时间: 2020年12月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients who are 20 years old or above at the time of informed consent
- •2. Patients with the ECOG performance status of 0 to 2 at the time of informed consent
- •3. Patients with a life expectancy of at least 90 days from the day of enrollment
- •4. Patients with a measurable lesion defined by the criteria of the RECIST version 1.1 according to the imaging during screening period
- •5. Patients judged by the (sub)investigator for whom the treatment may be continued R-OKY-034F-101 study
排除标准
- •1. Patients with active duplicate cancer
- •2. Patients with QTcE of over 500 msec
- •3. Patients weighing less than 40 kg at the time of informed consent
- •4. Patients who are considered inappropriate as a subject of this study by the (sub)investigator
研究者
相似试验
已完成
1 期
Phase I / IIa trial of R-OKY-034F for pancreatic cancer patientsC535836Pancreatic cancerJPRN-jRCT2051190003Takehara Tetsuo30
招募中
2 期
Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignanciesCancerACTRN12623001216606orthern Sydney Local Health District20
进行中（未招募）
1 期
The study to assess the efficacy and safety of new Interferon alpha-2b formulation in patients with primary myelofibrosisPrimary Myelofibrosis (grade MF-0 and MF-1) according to the WHO criteriaMedDRA version: 17.0 Level: LLT Classification code 10053134 Term: Osteomyelofibrosis System Organ Class: 100000004864EUCTR2014-001367-13-ATMedizinische Universtät Wien, Universitätsklinik für Innere Medizin I24
已完成
不适用
Phase I, single-center, open-label, two-period study to investigate the pharmacokinetics of the DMF-containing formulation FP187-V2B in healthy volunteers after oral administration in fasted and fed statepsoriasis10040790Multiple sclerosisNL-OMON46121Forward Pharma GmbH30
进行中（未招募）
1 期
A study of the effect of hydrogen peroxide foam in patients with bacterial vaginosisMedDRA version: 18.1Level: PTClassification code 10004055Term: Bacterial vaginosisSystem Organ Class: 10021881 - Infections and infestationsBacterial vaginosisEUCTR2015-003356-51-SEZelmic AB30